<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[provigil Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/provigil.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to provigil]]></description>
	<s:counts start="0" returned="7" found="7" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Generics Threaten Drugmaker Cephalon's Success]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004361/generics-threaten-drugmaker-cephalons-success/]]></link>
		<description><![CDATA[  Biotechnology watchers are measuring success at Cephalon on how quickly the drugmaker can convert patients on its soon-to-go generic blockbuster Provigil to regular users of its narcoleptic successor Nuvigil. As Jim Edwards at BNET Pharma astutely pointed out exactly one year ago, however, competition also threatens to derail...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 21 Sep 2009 08:38:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+watcher.html"><![CDATA[Biotechnology Watcher]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/nuvigil.html"><![CDATA[Nuvigil]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon Q2: Not Taking Nuvigil to Stay Awake Yet? You Will Be, Company Believes]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003496/cephalon-q2-not-taking-nuvigil-to-stay-awake-yet-you-will-be-company-believes/]]></link>
		<description><![CDATA[Cephalon is in the middle of a titanic struggle to move as many patients off its Provigil wakefulness drug onto its new brand, Nuvigil, which it just launched. Provigil goes off-patent sometime between now and April 2012, sooner if the FTC prevails in its anti pay-for-delay suit against the company....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 06 Aug 2009 11:38:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Is Cephalon's Provigil Addictive? Ask the Cocaine-Using Monkeys It Was Tested On.]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001397/is-cephalons-provigil-addictive-ask-the-cocaine-using-monkeys-it-was-tested-on/]]></link>
		<description><![CDATA[Cephalon is dealing with a PR storm over the question of whether Provigil, its sleep disorder drug, is addictive or not. A study by the National Institute on Drug Abuse suggests that it is:  Nora D. Volkow, MD, director of the National Institute on Drug Abuse NIDA, report[s] evidence...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 18 Mar 2009 20:45:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/monkey.html"><![CDATA[Monkey]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/modafinil.html"><![CDATA[Modafinil]]></category>
		<category domain="http://resources.bnet.com/topic/public+relations.html"><![CDATA[Public Relations]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Cephalon Hikes Provigil Prices, Icahn Eyes Amylin, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000406/pharma-roundup-cephalon-hikes-provigil-prices-icahn-eyes-amylin-and-more/]]></link>
		<description><![CDATA[Cephalon hopes Provigil price hikes now will keep its customers later. Icahn wants Amylin, perhaps. Johnson & Johnson pays for Duragesic death. Anti-depressants may be equivalent. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 18 Nov 2008 18:08:50 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/icahn.html"><![CDATA[Icahn]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/patches.html"><![CDATA[Patches]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">CEPH,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Cephalon: Damn the Torpedoes! We're Raising Prices!]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000403/cephalon-damn-the-torpedoes-were-raising-prices/]]></link>
		<description><![CDATA[A corporate strategy question for you about Cephalon: Your industry is unpopular because of its rising prices. Your company's marketing is under the control of the U.S. Department of Justice due to illegal off-label sales. One of your best-known brands is already facing generic competition, and one of your best-selling...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 18 Nov 2008 05:41:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[Brand]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/nuvigil.html"><![CDATA[Nuvigil]]></category>
		<category domain="http://resources.bnet.com/topic/provigil+sale.html"><![CDATA[Provigil Sale]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[Brand]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/nuvigil.html"><![CDATA[Nuvigil]]></category>
		<category domain="http://resources.bnet.com/topic/provigil+sale.html"><![CDATA[Provigil Sale]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000223/behind-cephalons-numbers-a-big-cancer-bet-and-signs-of-skepticism/]]></link>
		<description><![CDATA[The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being abused. Even though the Fentora situation is fixable, it's just the sort of headache...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 16 Sep 2008 09:13:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/revenue+picture.html"><![CDATA[Revenue Picture]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/nuvigil.html"><![CDATA[Nuvigil]]></category>
		<category domain="http://resources.bnet.com/topic/amrix.html"><![CDATA[Amrix]]></category>
		<category domain="http://resources.bnet.com/topic/treanda.html"><![CDATA[Treanda]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[FTC accuses Cephalon over Provigil in patent case]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmtpi/is_200802/ai_n24272487]]></link>
		<description><![CDATA[The Federal Trade Commission filed a lawsuit yesterday against Cephalon Inc. over deals it struck with four makers of generic drugs that had challenged the patent on Cephalon&#0039;s biggest drug, Provigil. The agreements, which the FTC said were worth more than $200 million, would prevent four companies - Teva Pharmaceutical...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 14 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ftc.html"><![CDATA[FTC]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
</channel>
</rss>
